MedTrace Logo

Topical Bevacizumab for Preventing Recurrent Pterygium

NCT01311960 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2013-04-09

No results posted yet for this study

Summary

The purpose of this study is to determine whether bevacizumab eye drop is effective in the treatment of recurrent pterygium.

Conditions

  • Pterygium
  • Bevacizumab
  • VEGF
  • Anti-VEGF

Interventions

DRUG

bevacizumab eye drop 0.05%

bevacizumab eye drop 0.05% will apply 4 times a day for 3 months

DRUG

normal saline 0.9%

normal saline eye drop 0.9% will apply 4 times a day for 3 months.

Sponsors & Collaborators

  • Chulalongkorn University

    lead OTHER

Principal Investigators

  • Ngamjit Kasetsuwan, MD · Chulalongkorn Universitiy

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2013-03-31
Completion
2013-04-30

Countries

  • Thailand

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01311960 on ClinicalTrials.gov